Cue Biopharma, Inc. — Director's Dealing 2021

Feb 19, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Cue Biopharma, Inc. (CUE)
CIK: 0001645460
Period of Report: 2021-02-16

Reporting Person: Pienta Kenneth (Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-02-16	Common Stock	M	16000	$2.86	Acquired	18000	Direct
2021-02-16	Common Stock	S	16000	$15.1514	Disposed	2000	Direct
2021-02-17	Common Stock	M	1280	$2.86	Acquired	3280	Direct
2021-02-17	Common Stock	M	2994	$5.00	Acquired	6274	Direct
2021-02-17	Common Stock	S	4274	$15.055	Disposed	2000	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-02-16	Stock Option (right to buy)	$2.86	M	16000	Disposed	2023-11-16	Common Stock (16000)	Direct
2021-02-17	Stock Option (right to buy)	$2.86	M	1280	Disposed	2023-11-16	Common Stock (1280)	Direct
2021-02-17	Stock Option (right to buy)	$5.00	M	2994	Disposed	2024-04-17	Common Stock (2994)	Direct

Footnotes

F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 20, 2020.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.06 to $15.60, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc., any security holder of Cue Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (2) to this Form 4.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.20, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc., any security holder of Cue Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (3) to this Form 4.

F4: The option, representing a right to purchase a total of 20,000 shares, became exercisable in full on November 16, 2017.

F5: The option, representing a right to purchase a total of 150,000 shares, vests in four equal annual installments beginning December 31, 2017.